查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1698453

肉毒桿菌毒素市场：2025-2030 年预测

Botulinum Toxin Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

肉毒桿菌毒素市场预计将从 2025 年的 85.9 亿美元成长到 2030 年的 121.81 亿美元，预测期内的复合年增长率为 7.23%。

肉毒桿菌毒素是由革兰氏阳性厌氧菌肉毒梭菌产生的。肉毒桿菌毒素市场的主要成长动力是人口老化、微创手术的增加、脸部美容手术的激增、非手术选择数量的增加以及技术创新的进步。其中包括一项关键创新：延长 A 型肉毒桿菌毒素的作用时间。另一个主要驱动因素是新兴市场医疗保健支出的增加。

市场趋势：

  • 技术进步和新产品开发：技术创新和有希望的研究成果促使製造商开发新产品并力求迅速采用。例如，2024 年 9 月，AEON Biopharma 根据 351(k) 生物相似药途径开发了肉毒桿菌复合物。该公司已收到与美国食品药物管理局(FDA) 就 ABP-450（prabotulinumtoxinA）注射（BOTOX（onabotulinumtoxinA）的生物相似药）举行的生物相似药初步咨询 (BIA) 会议的正式记录。
  • 微创手术的需求不断增加：在技术进步的推动下，肉毒桿菌毒素在微创手术中的应用越来越多。神经调节注射，如肉毒桿菌和真皮填充剂，可以立即产生效果，停机时间最短，已成为保持美丽的重要部分。根据美国整形外科医师协会的数据，2023 年美国使用 A 型肉毒桿菌毒素（包括 Botox、 Dysport和Xeomin）的手术记录为 4,715,716 例，与前一年同期比较增加了 6%。
  • 新兴经济体的市场不断增长：由于可支配收入的增加和整装仪容意识的增强，中国等国家对肉毒桿菌的需求巨大。
  • 北美处于领先地位：北美仍然是肉毒桿菌毒素的最大消费国，神经调节剂注射被广泛用于减少皱纹和细纹。软组织填充剂也越来越受欢迎，可以恢復皮肤的体积和水分。 2023 年，使用神经调节剂注射（Botox、 Dysport、 Xeomin、Jeuveau、Daxify）的微创美容手术达到 9,480,949 例，与前一年同期比较增长 9%。预计这种不断增长的需求将进一步推动市场扩张。

报告中介绍的关键公司包括益普生集团 (Ipsen Group)、Metabiologics、Merz Pharma、Galderma、AbbVie Inc.、Medytox、兰州生物製品研究所有限责任公司、HUGEL, Inc.、Evolus, Inc.、Revance Therapeutics, Inc. 和 Supernus Pharmaceuticals, Inc.。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测包括国家在内的细分市场和地区分析
  • 公司概况（策略、产品、财务资讯、主要趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔

第三章 商业景气

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 肉毒桿菌毒素市场（依产品类型）

  • 介绍
  • A型肉毒桿菌毒素
  • B型肉毒桿菌

第六章肉毒桿菌市场（依应用）

  • 介绍
  • 美学应用
  • 治疗应用

7. 肉毒桿菌毒素市场（依最终用户）

  • 介绍
  • 医院
  • 诊所
  • 化妆品中心

8. 肉毒桿菌毒素市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 台湾
    • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Ipsen Group
  • Metabiologics
  • Merz Pharma
  • Galderma
  • AbbVie Inc.
  • Medytox
  • Lanzhou Institute of Biological Products Co., Ltd.
  • HUGEL, Inc.
  • Evolus, Inc.
  • Revance Therapeutics, Inc.
  • Supernus Pharmaceuticals, Inc.

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615633

The Botulinum Toxins Market, valued at US$12.181 billion in 2030 from US$8.590 billion in 2025, is projected to grow at a CAGR of 7.23% through 2030.

Botulinum toxin is made from Clostridium botulinum, a gram-positive anaerobic bacterium. The major growth drivers for the botulinum toxin market are the aging population, increasing numbers of minimally invasive surgeries, upsurge in facial aesthetics procedures, the rising alternative of non-surgical procedures, and advancement in innovation. This includes increasing the duration of action for Botulinum Toxin Type A, which has been an important innovation. Besides, increased healthcare spending in emerging markets is a major driving factor.

Market Trends:

  • Technological advancements and new product development: Innovations in technology and promising research outcomes have motivated manufacturers to create new products for quicker adoption. For example, in September 2024, AEON Biopharma, Inc. developed a botulinum toxin complex under the 351(k) biosimilar pathway. The company received formal minutes from a Biosimilar Initial Advisory (BIA) meeting with the U.S. Food and Drug Administration (FDA) for ABP-450 (prabotulinumtoxinA) injection, a biosimilar to BOTOX (onabotulinumtoxinA).
  • Rising demand for minimally invasive treatments: Botulinum toxins are increasingly used in minimally invasive procedures, a trend fueled by technological progress. Neuromodulator injections like Botox and dermal fillers have become integral to aesthetic maintenance, offering immediate results with minimal downtime. In 2023, the U.S. recorded 4,715,716 procedures using botulinum toxin type A (including Botox, Dysport, and Xeomin), marking a 6% increase from the previous year, according to the American Society of Plastic Surgeons.
  • Growing market in emerging economies: Countries like China are witnessing significant demand for botulinum toxins, driven by rising disposable incomes and heightened awareness of personal appearance. This has expanded the market, as more individuals are willing to invest in cosmetic treatments.
  • North America's leading role: North America remains a major consumer of botulinum toxins, with neuromodulator injections widely used to reduce wrinkles and fine lines. Soft tissue fillers are also increasingly popular for restoring volume and hydration to the skin. In 2023, cosmetic minimally invasive procedures using neuromodulator injections (Botox, Dysport, Xeomin, Jeuveau, Daxxify) reached 9,480,949, a 9% increase from the previous year. This growing demand is expected to further drive market expansion.

Some of the major players covered in this report include Ipsen Group, Metabiologics, Merz Pharma, Galderma, AbbVie Inc., Medytox, Lanzhou Institute of Biological Products Co., Ltd., HUGEL, Inc., Evolus, Inc., Revance Therapeutics, Inc., and Supernus Pharmaceuticals, Inc., among others:

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Botulinum Toxins Market is analyzed into the following segments:

By Product Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By Application

  • Aesthetic Applications
  • Therapeutic Applications

By End User

  • Hospitals
  • Clinics
  • Cosmetic Centers

By Region

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BOTULINUM TOXINS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Botulinum Toxin Type A
  • 5.3. Botulinum Toxin Type B

6. BOTULINUM TOXINS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Aesthetic Applications
  • 6.3. Therapeutic Applications

7. BOTULINUM TOXINS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Cosmetic Centers

8. BOTULINUM TOXINS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Application
    • 8.3.3. By End User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Application
    • 8.4.3. By End User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By End User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Application
    • 8.6.3. By End User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Ipsen Group
  • 10.2. Metabiologics
  • 10.3. Merz Pharma
  • 10.4. Galderma
  • 10.5. AbbVie Inc.
  • 10.6. Medytox
  • 10.7. Lanzhou Institute of Biological Products Co., Ltd.
  • 10.8. HUGEL, Inc.
  • 10.9. Evolus, Inc.
  • 10.10. Revance Therapeutics, Inc.
  • 10.11. Supernus Pharmaceuticals, Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations